Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedA site-wide NIH notice announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) and links to updates and FAQs.SummaryDifference1%

- Check8 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.1 to v3.7.2 on the error page.SummaryDifference0.2%

- Check15 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the expected study details and navigation. This indicates the page is currently inaccessible due to access restrictions or server configuration.SummaryDifference17%

- Check57 days agoChange DetectedThe page shows a new revision tag (v3.6.6) indicating a new build or patch, but the study details and visible content remain unchanged.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page now includes the full study details with attached documents (Study Protocol and Statistical Analysis Plan) and expanded metadata. The previous error page content has been removed, restoring access to the study record.SummaryDifference41%

Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.